Generation of the human induced pluripotent stem cell line UKWNLi010 derived from a patient carrying two homozygous single nucleotide polymorphisms (rs2839629 and rs915854) associated with an increased risk of painful bortezomib-induced peripheral neuropathy.

Bortezomib-induced peripheral neuropathy (BIPN) is a frequent, dose-limiting side effect in multiple myeloma (MM) patients treated with the proteasome inhibitor bortezomib (BTZ). To study the pathophysiology of pain in BIPN, we generated three induced pluripotent stem cell (iPSC) clones from human dermal fibroblasts (hdF) of a MM patient who developed painful BIPN and carried two homozygous risk variants (rs2839629 and rs915854). All clones exhibited typical iPSC morphology, expressed pluripotency markers, possessed normal karyotypes, and differentiated into all three germ layers. This patient-specific iPSC line provides an in vitro model to investigate genetic susceptibility and molecular mechanisms underlying pain in BIPN.